Clarius Group LLC Acquires 8,061 Shares of Bristol-Myers Squibb (NYSE:BMY)

Clarius Group LLC raised its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 98.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 16,235 shares of the biopharmaceutical company’s stock after acquiring an additional 8,061 shares during the quarter. Clarius Group LLC’s holdings in Bristol-Myers Squibb were worth $674,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in BMY. Strategic Blueprint LLC grew its position in shares of Bristol-Myers Squibb by 78.6% during the fourth quarter. Strategic Blueprint LLC now owns 9,715 shares of the biopharmaceutical company’s stock valued at $498,000 after purchasing an additional 4,275 shares in the last quarter. Pinnacle Bancorp Inc. grew its position in Bristol-Myers Squibb by 9.8% in the fourth quarter. Pinnacle Bancorp Inc. now owns 2,761 shares of the biopharmaceutical company’s stock worth $142,000 after acquiring an additional 247 shares in the last quarter. RFG Advisory LLC boosted its position in shares of Bristol-Myers Squibb by 6.3% during the fourth quarter. RFG Advisory LLC now owns 18,016 shares of the biopharmaceutical company’s stock valued at $924,000 after buying an additional 1,064 shares during the period. Allspring Global Investments Holdings LLC boosted its position in shares of Bristol-Myers Squibb by 11.4% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,740,153 shares of the biopharmaceutical company’s stock valued at $89,287,000 after buying an additional 177,387 shares during the period. Finally, Turtle Creek Wealth Advisors LLC purchased a new position in shares of Bristol-Myers Squibb during the fourth quarter valued at approximately $40,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Performance

BMY traded up $0.25 on Friday, reaching $47.10. The company had a trading volume of 3,804,003 shares, compared to its average volume of 15,900,625. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $63.41. The stock has a market capitalization of $95.48 billion, a PE ratio of -15.11, a P/E/G ratio of 12.51 and a beta of 0.44. The company has a quick ratio of 0.99, a current ratio of 1.16 and a debt-to-equity ratio of 2.86. The stock has a 50-day moving average price of $42.91 and a 200-day moving average price of $46.67.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.64 by $0.43. Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 12.51%. The business had revenue of $12.20 billion for the quarter, compared to analyst estimates of $11.54 billion. During the same period in the previous year, the business posted $1.75 earnings per share. The business’s revenue was up 8.7% compared to the same quarter last year. As a group, research analysts forecast that Bristol-Myers Squibb will post 0.77 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, August 1st. Stockholders of record on Friday, July 5th were given a $0.60 dividend. The ex-dividend date was Friday, July 5th. This represents a $2.40 annualized dividend and a dividend yield of 5.10%. Bristol-Myers Squibb’s dividend payout ratio is presently -77.42%.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on BMY. StockNews.com upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 29th. Wells Fargo & Company lifted their price target on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research note on Thursday, April 18th. BMO Capital Markets decreased their price target on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research note on Friday, April 26th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $45.00 price target on shares of Bristol-Myers Squibb in a research note on Monday, July 22nd. Finally, Deutsche Bank Aktiengesellschaft reduced their price objective on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a research note on Tuesday, July 23rd. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Bristol-Myers Squibb currently has an average rating of “Hold” and an average price target of $55.79.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.